Follow
Sveinbjörn Gizurarson
Sveinbjörn Gizurarson
Professor of Clinical Pharmacokinetics and Biopharmaceutics, University of Iceland
Verified email at hi.is
Title
Cited by
Cited by
Year
Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia
DL Rolnik, D Wright, LC Poon, N O’Gorman, A Syngelaki, ...
New England Journal of Medicine 377 (7), 613-622, 2017
20042017
Evaluation of intranasal delivery route of drug administration for brain targeting
F Erdő, LA Bors, D Farkas, Á Bajza, S Gizurarson
Brain research bulletin 143, 155-170, 2018
5712018
Anatomical and histological factors affecting intranasal drug and vaccine delivery
S Gizurarson
Current drug delivery 9 (6), 566-582, 2012
2492012
Animal models for intranasal drug delivery studies. A review article.
S Gizurarson
Acta pharmaceutica nordica 2 (2), 105-122, 1990
1691990
The relevance of nasal physiology to the design of drug absorption studies
S Gizurarson
Advanced drug delivery reviews 11 (3), 329-347, 1993
1331993
Method of administering a biologically active substance
E Bechgaard, S Gizurarson, RK Hjortkjaer
US Patent 5,428,006, 1995
1271995
Pharmaceutical preparation
E Bechgaard, S Gizurarson, RK Hjortkjaer
US Patent 5,397,771, 1995
1151995
Placental protein 13 (PP13)–a placental immunoregulatory galectin protecting pregnancy
NG Than, A Balogh, R Romero, É Kárpáti, O Erez, A Szilágyi, I Kovalszky, ...
Frontiers in immunology 5, 102497, 2014
1132014
The effect of cilia and the mucociliary clearance on successful drug delivery
S Gizurarson
Biological and Pharmaceutical Bulletin 38 (4), 497-506, 2015
1122015
Method of administering a biologically active substance
E Bechgaard, S Gizurarson
US Patent 5,693,608, 1997
1071997
Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia
B Huppertz, H Meiri, S Gizurarson, G Osol, M Sammar
Human reproduction update 19 (4), 391-405, 2013
922013
Intranasal administration of insulin to humans
S Gizurarson, E Bechgaard
Diabetes research and clinical practice 12 (2), 71-84, 1991
801991
The influence of insulin and some excipients used in nasal insulin preparations on mucociliary clearance
S Gizurarson, C Marriott, GP Martin, E Bechgaard
International journal of pharmaceutics 65 (3), 243-247, 1990
691990
Modulation of immune responses using adjuvants to facilitate therapeutic vaccination
V Schijns, A Fernández‐Tejada, Ž Barjaktarović, I Bouzalas, J Brimnes, ...
Immunological reviews 296 (1), 169-190, 2020
672020
Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections
H Jakobsen, E Saeland, S Gizurarson, D Schulz, I Jónsdóttir
Infection and immunity 67 (8), 4128-4133, 1999
671999
Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit
S Gizurarson, S Tamura, C Aizawa, T Kurata
Vaccine 10 (2), 101-106, 1992
661992
Absorption promoting agent
S Gizurarson, S Olafsdottir, JL Kristinsson, K Hrafnkelsdottir, DR Olafsson, ...
US Patent 6,855,332, 2005
602005
Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits
E Bechgaard, S Gizurarson, RK Hjortkjćr
Journal of pharmacy and pharmacology 49 (8), 747-750, 1997
601997
Intranasal booster vaccination against diphtheria and tetanus in man
H Aggerbeck, S Gizurarson, J Wantzin, I Heron
Vaccine 15 (3), 307-316, 1997
601997
Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
S Gizurarson, I Heron
US Patent 5,942,237, 1999
591999
The system can't perform the operation now. Try again later.
Articles 1–20